|
| PamGene Platform Adopted for Kinase Drug R&D Program: Collaboration with J&JPRD | | | 's-Hertogenbosch, The Netherlands, 9th March 2006
PamGene International BV of 's-Hertogenbosch, The Netherlands, and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica NV of Beerse, Belgium, have announced significant progress in their kinase profiling collaboration. After extensive evaluation, PamGene's microarray-based biochemical kinase activity profiling and cellular inhibition assays will be further implemented in J&JPRD's research programs.
The evaluation program involved kinase inhibitor characterization on a panel of recombinant kinases. Additionally, a number of reference and J&JPRD proprietary kinase inhibitors were characterized in whole cell-based experiments. Kinase activity was measured by phosphorylation profiles (fingerprints) obtained from the kinetic readout from lysates of compound-treated cells.
About PamGene
PamGene was founded in 1999 in 's-Hertogenbosch, The Netherlands. Its 3-dimensional flow-through microarray technology is used for analysis of both proteins and nucleic acids. PamGene supports drug discovery in areas including compound profiling in diseases concerning, amongst others, kinases. Selectivity and potency data, quickly and easily generated on PamGene's PamStation® instruments, enables pharmaceutical companies to select compounds with improved chances of success in drug development.
For more information contact:
PamGene International BV
Morven Brodie
Communications Manager
PO Box 1345
5200 BJ 's-Hertogenbosch
The Netherlands
Tel.: +31 (0)73 6158 967
Fax: +31 (0)73 6158 081
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.pamgene.com
| |
